XML 60 R48.htm IDEA: XBRL DOCUMENT v3.21.1
License Agreements - Agenus (Details)
$ / shares in Units, $ in Thousands, shares in Millions
1 Months Ended 3 Months Ended 12 Months Ended
Feb. 14, 2017
USD ($)
$ / shares
Feb. 01, 2017
USD ($)
$ / shares
shares
Nov. 30, 2015
item
Jan. 31, 2015
item
Mar. 31, 2021
USD ($)
$ / shares
shares
Sep. 30, 2020
USD ($)
$ / shares
shares
Jun. 30, 2020
USD ($)
$ / shares
shares
Mar. 31, 2020
USD ($)
Mar. 31, 2017
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2020
USD ($)
Feb. 28, 2017
USD ($)
License agreements                        
Long term investments         $ 202,174           $ 222,301 [1]  
Unrealized gain (loss) on long term investments         (27,709)     $ (48,132)        
Research and development expense         $ 306,896     1,085,287        
Agenus                        
License agreements                        
Number of program targets | item     3 4                
Royalty payments on future global net sales (as a percent)         15.00%              
Agenus | Development, Regulatory and Commercialization Milestones | Minimum                        
License agreements                        
Royalty payments on future global net sales (as a percent)         6.00%              
Agenus | Development, Regulatory and Commercialization Milestones | Maximum                        
License agreements                        
Royalty payments on future global net sales (as a percent)         12.00%              
Additional milestone payments under the license agreement                       $ 500,000
Agenus | Development Milestones                        
License agreements                        
Upfront payment under license agreement                   $ 20,000    
Additional milestone payments under the license agreement         $ 10,000              
Agenus                        
License agreements                        
Long term investments         $ 37,700           44,700  
Ownership percentage (as a percent) 18.00%       7.00%              
Shares divested (in shares) | shares         0.2 2.5 1.2          
Share price (per share) | $ / shares         $ 5.45              
Gross proceeds from sale of stock         $ 1,100 $ 12,700 $ 4,500          
Unrealized gain (loss) on long term investments         (5,900)     28,800        
Research and development expense         500     $ 100        
Agenus | Accrued and other liabilities                        
License agreements                        
Accrued and other liabilities         $ 500           $ 500  
Agenus | Minimum                        
License agreements                        
Share price (per share) | $ / shares           $ 4.28 $ 3.57          
Agenus | Maximum                        
License agreements                        
Share price (per share) | $ / shares           $ 5.25 $ 4.21          
Agenus | Stock purchase agreement                        
License agreements                        
Total consideration paid $ 60,000                      
Purchase of common stock under Stock Purchase Agreement (in shares ) | shares   10.0                    
Purchase price of common stock   $ 60,000                    
Per share price | $ / shares $ 4.40 $ 6.00                    
Discount for lack of marketability $ 4,500                      
Fair value of shares on the issuance date $ 39,500                      
Long term investments                 $ 39,500      
Research and development expense                 $ 20,500      
[1] The condensed consolidated balance sheet at December 31, 2020 has been derived from the audited consolidated financial statements at that date.